Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
6(60.0%)
Phase 1
2(20.0%)
Phase 4
2(20.0%)
10Total
N/A(6)
Phase 1(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT03610334Phase 1Completed

A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088

Role: collaborator

NCT03988556Not ApplicableCompleted

Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis

Role: collaborator

NCT02963519Not ApplicableUnknown

Evaluation of Improved Preparation Time to a Coverage in Patients With Acute Wounds by Use of VistaCare® Versus Dressings

Role: lead

NCT01861639Not ApplicableTerminated

Stability of rTMS on Cognition and Brain Networks on Healthy Subjects.

Role: lead

NCT01425957Not ApplicableCompleted

Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment

Role: lead

NCT02020824Not ApplicableUnknown

Virtual Reality and Concept of Control in the Treatment of Acrophobia

Role: lead

NCT01461174Phase 1Completed

Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers

Role: lead

NCT01109147Phase 4Completed

Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients

Role: lead

NCT01490021Not ApplicableTerminated

Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects

Role: lead

NCT01048229Phase 4Terminated

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Role: lead

All 10 trials loaded